• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Dermatologist Mona Shahriari, MD, Talks Nonsteroidal Topicals for Atopic Dermatitis

Commentary
Video

There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer.

"To address the limitations of topical corticosteroids, we have a next generation of topical noncorticosteroid drugs with varying mechanisms of action that all target the specific underlying pathophysiology of atopic dermatitis."

Mona Shahriari, MD, a dermatologist and assistant clinical professor of dermatology at Yale University School of Medicine, sat down with Patient Care recently and provided a detailed overview of the 3 classes of topical treatments for atopic dermatitis that do not have the broad immunosuppressive properties of the corticosteroids and have proven highly effective. In the video segment above, Shahriari toplines the most important features, including dosing and potential adverse events, of each medication:

Ruxolitinib, a topical selective Janus kinase (JAK)1/JAK2 inhibitor, was approved by the FDA in September 2021 and is marketed as Opzelura (Incyte)

Roflumilast, approved by the FDA in July 2024, is a phosphodiesterase-4 (PDE4) inhibitor and marketed as Zoryve (Arcutis Biotherapeutics)

Tapinarof 1% is an investigational aryl hydrocarbon receptor agonist currently under review by the FDA; the agency has set at PDUFA date in the 4th quarter of 2024.

Mona Shahriari, MD, is assistant clinical professor of dermatology at Yale University School of Medicine in New Haven, Connecticut and co-founder of Central Connecticut Dermatology in Cromwell, Connecticut.

Related Content
Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD / image credit Central Connecticut Dermatology

Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD

Grace Halsey
November 6th 2024
Article

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children / image credit ©Organon

FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children

Grace Halsey
November 5th 2024
Article

The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.

Atopic Dermatitis: Final ADORING 3 Open-Lael Extension Trial Findings with Tapinarof 1% Announced / image credit atopic dermatitis concept ©New Africa/stock.adobe.com

Atopic Dermatitis: Final ADORING 3 Open-Label Extension Trial Findings with Tapinarof Cream, 1% Announced

Grace Halsey
October 31st 2024
Article

Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.

Dupilumab Efficacy for Severe Atopic Dermatitis Durable at 5 Years: New Data

Dupilumab Efficacy for Severe Atopic Dermatitis Durable at 5 Years: New Data

Ryan Flinn
October 25th 2024
Article

After 60 months of treatment, 38% of study participants with severe AD achieved complete remission.

Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years / image credit - Lilly logo: ©Michael Vi/stock.adobe.com

Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years

Grace Halsey
September 25th 2024
Article

Among adolescents and adults with moderate-to-severe AD, more than 80% achieved sustained disease control, the majority not requiring topical or systemic rescue medication.

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types / Image credit: ©InfiniteStudio/AdobeStock

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types

Sydney Jennings
September 25th 2024
Article

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

© 2024 MJH Life Sciences

All rights reserved.